Treatment with GLP1-RA did not reduce the risk of HHF in T2DM patients with HF history, particularly HFrEF, but may prevent new-onset HF in T2DM patients without HF [30, 40, 41]. This evidence concerns the gene GLP1R and hydrops fetalis.